TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Phase 1
Completed
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT00052065
- Lead Sponsor
- Telik
- Brief Summary
This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie TLK286's activity in platinum-resistant ovarian cancer?
How does TLK286 combination therapy compare to standard-of-care in advanced ovarian cancer?
Which biomarkers correlate with TLK286 response in NCT00052065 ovarian cancer trials?
What adverse events were reported in TLK286 and Doxil combination trials for ovarian cancer?
Are there alternative PARP inhibitor combinations to TLK286 for platinum-resistant ovarian cancer?
Trial Locations
- Locations (1)
M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
M.D. Anderson Cancer Center🇺🇸Houston, Texas, United States